Emergent BioSolutions (EBS) Cost of Revenue (2011 - 2026)

Emergent BioSolutions' Cost of Revenue history runs 16 years deep, the most recent figure standing at $72.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 18.64% year-over-year to $72.0 million; the TTM figure through Mar 2026 stood at $309.7 million (down 18.31% YoY), while the FY2025 annual figure was $326.2 million, down 52.12% from the prior year.
• Cost of Revenue was $72.0 million for Q1 2026 at Emergent BioSolutions, down from $84.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $190.6 million in Q2 2023 to a low of $900000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $110.1 million across 5 years, with a median of $88.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue plunged 98.07% in 2022, then jumped 16888.89% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $167.3 million in 2022, then grew by 10.64% to $185.1 million in 2023, then plunged by 36.25% to $118.0 million in 2024, then fell by 28.05% to $84.9 million in 2025, then declined by 15.19% to $72.0 million in 2026.
• The last three Cost of Revenue figures came in at $72.0 million (Q1 2026), $84.9 million (Q4 2025), and $85.9 million (Q3 2025), per Business Quant data.